Entrada Therapeutics (NASDAQ:TRDA) Trading Down 8.4%

Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Free Report)’s share price traded down 8.4% during trading on Tuesday . The company traded as low as $14.86 and last traded at $15.00. 18,422 shares changed hands during trading, a decline of 78% from the average session volume of 82,953 shares. The stock had previously closed at $16.37.

Analysts Set New Price Targets

Several analysts have issued reports on TRDA shares. HC Wainwright dropped their price objective on Entrada Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, November 27th. Oppenheimer initiated coverage on Entrada Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $22.00 price target on the stock.

Get Our Latest Report on Entrada Therapeutics

Entrada Therapeutics Stock Up 3.9 %

The stock’s 50 day moving average is $14.83 and its 200 day moving average is $15.28.

Entrada Therapeutics (NASDAQ:TRDAGet Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $1.57. The firm had revenue of $43.74 million for the quarter, compared to the consensus estimate of $16.31 million. Equities analysts forecast that Entrada Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 10,206 shares of the stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $15.69, for a total transaction of $160,132.14. Following the transaction, the chief financial officer now owns 49,571 shares in the company, valued at approximately $777,768.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 12,300 shares of company stock worth $192,929 in the last ninety days. 7.58% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. grew its position in Entrada Therapeutics by 563.2% during the second quarter. BlackRock Inc. now owns 1,405,806 shares of the company’s stock worth $21,284,000 after buying an additional 1,193,821 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Entrada Therapeutics by 21.9% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,972,050 shares of the company’s stock worth $46,840,000 after purchasing an additional 534,552 shares in the last quarter. State Street Corp increased its position in shares of Entrada Therapeutics by 505.8% in the second quarter. State Street Corp now owns 391,191 shares of the company’s stock worth $5,923,000 after purchasing an additional 326,614 shares during the period. Geode Capital Management LLC raised its stake in Entrada Therapeutics by 118.0% in the second quarter. Geode Capital Management LLC now owns 400,631 shares of the company’s stock valued at $6,066,000 after purchasing an additional 216,841 shares in the last quarter. Finally, Nan Fung Group Holdings Ltd acquired a new position in Entrada Therapeutics in the first quarter valued at about $1,630,000. 77.59% of the stock is owned by institutional investors.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1.

Read More

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.